Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alliance Medical

This article was originally published in The Gray Sheet

Executive Summary

Reprocessor of disposable medical devices raises $8 mil. in second round of financing, increasing to $16.5 mil. the amount the firm has raised in the past 12 months to support ongoing activities and growth. Coral Ventures, Delphi Ventures, Valley Ventures, and Patricof & Co. Ventures participated in the financing. With the Aug. 2 release of FDA's guidance on single-use device reuse, "we believe that the company will become the undisputed leader in an industry poised for dramatic growth," Patricof Managing Director Janet Effland comments. The guidance "will lead to a tremendous surge in demand for reprocessing by third-party reprocessors that can meet the new requirements" (1"The Gray Sheet" Aug. 7, 2000, p. 5). Alliance CEO Rick Ferreira commented that the financing strengthens the Phoenix-based company's "ability to respond to the expensive, labor intensive pre-market requirements the FDA recently mandated for all organizations that reprocess medical devices"

You may also be interested in...



SUD Reprocessing Guidance Retains Premarket Exemptions For Now

FDA has not yet decided whether it will retain premarket exemptions for reprocessed Class I/II single-use devices (SUDs), according to the Aug 2 final guidance "Enforcement Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals."

Health And Wellness Trademark Review 1 December, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Ipsen CEO Outlines Strategy For Long-Term Success

While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel